NASDAQ: BBOT
Bridgebio Oncology Therapeutics Inc Stock Ownership - Who owns Bridgebio Oncology Therapeutics?

Insider buying vs selling

Have Bridgebio Oncology Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Bihua ChenDirector2025-08-11760,496$10.72
$8.15MBuy
Bihua ChenDirector2025-08-11639,110$10.72
$6.85MBuy
Bihua ChenDirector2025-08-115,598,425$10.72
$60.00MBuy

1 of 1

BBOT insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when BBOT insiders and whales buy or sell their stock.

BBOT Shareholders

What type of owners hold Bridgebio Oncology Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Bihua Chen30.74%18,782,194$181.25MInsider
Bridgebio Pharma LLC22.59%13,805,126$133.22MInsider
Cormorant Asset Management LP4.76%2,909,000$28.07MInstitution
Blackrock Inc2.45%1,498,865$14.46MInstitution
Citadel Advisors LLC2.34%1,427,201$13.77MInstitution
Adage Capital Partners GP LLC2.29%1,400,000$13.51MInstitution
Price T Rowe Associates Inc1.75%1,071,550$10.34MInstitution
Millennium Management LLC1.47%897,251$8.66MInstitution
Sculptor Capital LP1.31%800,000$7.72MInstitution
Silverarc Capital Management LLC1.00%613,393$5.92MInstitution

1 of 3

BBOT vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
BBOT27.36%54.31%Net BuyingNet Buying
SEPN66.18%33.82%Net BuyingNet Buying
ORKA18.34%81.66%Net Buying
GOSS77.95%14.64%Net BuyingNet Buying
SVRA40.00%60.00%Net BuyingNet Buying

Bridgebio Oncology Therapeutics Stock Ownership FAQ

Who owns Bridgebio Oncology Therapeutics?

Bridgebio Oncology Therapeutics (NASDAQ: BBOT) is owned by 27.36% institutional shareholders, 54.31% Bridgebio Oncology Therapeutics insiders, and 18.33% retail investors. Bihua Chen is the largest individual Bridgebio Oncology Therapeutics shareholder, owning 18.78M shares representing 30.74% of the company. Bihua Chen's Bridgebio Oncology Therapeutics shares are currently valued at $167.91M.

If you're new to stock investing, here's how to buy Bridgebio Oncology Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.